TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05071339
Drug: Ganirelix Acetate, Cetrolix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
Study: NCT05035498
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
Study: NCT04629729
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning agent
Study: NCT04629729
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic response modifier
Study: NCT04629729
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT05465135
Drug: Dihydroartemisinin
Normalized name: Dihydroartemisinin
DrugBank: Artenimol (DB11638)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
Study: NCT05182164
Drug: Association of pembrolizumab + cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.
Study: NCT04814537
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Anesthetic Agent
Study: NCT05453799
Drug: Vudalimab
Normalized name: Vudalimab
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05863936
Drug: Belimumab Injection
Normalized name: belimumab Injection
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
Study: NCT05485103
Drug: Polyethylene Glycols
Normalized name: polyethylene glycols
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
Study: NCT05356793
Drug: SCH-1
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel anti-infective eyedrop
Study: NCT05619848
Drug: Rocuronium Bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
Study: NCT05290220
Drug: HLX07
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg
Study: NCT05290220
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg
Study: NCT05290220
Drug: HLX04
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg
Study: NCT05290220
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
Study: NCT05596981
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT05559814
Drug: Intraluminal peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
Study: NCT04515836
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
Study: NCT05902728
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg
Study: NCT05902728
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg
Study: NCT05076422
Drug: BI 3006337
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 3006337
Study: NCT06008379
Drug: 7MW3711 for injection
Normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of 7MW3711, Q3W, 3 weeks a cycle
Study: NCT06008379
Drug: 7MW3711 for injection
Normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Study: NCT06033989
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
Study: NCT05158062
Drug: olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: olaparib 300 mg twice daily (BID) during maintenance period
Study: NCT05158062
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC=5 or 6 Q3W during treatment period
Study: NCT05158062
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m2 Q3W during treatment period
Study: NCT05158062
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
Study: NCT06767761
Drug: GZR4
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GZR4 s.c., once-weekly，treat-to-target dose
Study: NCT06767761
Drug: Insulin Glargine U100 group
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
Study: NCT05347069
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg/day
Study: NCT04632199
Drug: 111In-IPN01087 Low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered once via slow intravenous injection.
Study: NCT04632199
Drug: 111In-IPN01087 High dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once via slow intravenous injection.
Study: NCT00014742
Drug: collagenase
Normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06001580
Drug: BR101
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
Study: NCT06040177
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
Study: NCT05418049
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg - Supplied as 10mg and 20mg tablets
Study: NCT05418049
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 10 mg tablets
Study: NCT05418049
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mcg capsule
Study: NCT05938036
Drug: ALT-100 mAb
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
Study: NCT05938036
Drug: ALT-100 (Placebo)
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution via IV solution
Study: NCT06528314
Drug: Efruxifermin
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT06670196
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg, QD
Study: NCT06669351
Drug: Oseltamivir phosphate dry suspension
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label.
Study: NCT06670105
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by vein
Study: NCT05347485
Drug: Cilta-cel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilta-cel will be administered as an IV infusion.
Study: NCT04880811
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib is orally administered at 40mg Qd of each 21 day cycle.
Study: NCT04880811
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
Study: NCT05449392
Drug: Neosporin
Normalized name: Neosporin
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
Study: NCT04898907
Drug: Moxifloxacin Hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive 400 mg, Oral, Fasted
Study: NCT05732129
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg,orally, bid (days 1-7) every 2 weeks
Study: NCT05732129
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
Study: NCT01543750
Drug: 4-Aminopyridine
Normalized name: 4-aminopyridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04919564
Drug: Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)
Normalized name: furosemide in 0.9 % NaCl 100 mg/100 mL (1 mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 2 mg/hour infusion for 12 hours since induction
Study: NCT05629962
Drug: Bemnifosbuvir (BEM)
Normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
Study: NCT05137938
Drug: Intranasal Ketamine (IN)
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
Study: NCT05503953
Drug: AGLS
Normalized name: Aglucosidase alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Uptitration
Study: NCT06526520
Drug: Exposure to progesterone or HRT medication
Normalized name: Medicated Pad or Tape
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Study: NCT06058793
Drug: Brigimadlin
Normalized name: Brigimadlin
DrugBank: Brigimadlin (DB18578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigimadlin
Study: NCT04734873
Drug: CPI-006 2 mg/kg + SOC
DrugBank: CPI-006 (DB16488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
Study: NCT04734873
Drug: CPI-006 1 mg/kg + SOC
DrugBank: CPI-006 (DB16488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
Study: NCT06010810
Drug: 3 % Topical Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
Study: NCT06340711
Drug: OBP-301
Normalized name: DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
Study: NCT06340711
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
Study: NCT05357183
Drug: PEG-IFN
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
Study: NCT06334133
Drug: Cadisegliatin 800 mg QD
Normalized name: Cadisegliatin
DrugBank: Cadisegliatin (DB18886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Study: NCT06334133
Drug: Cadisegliatin 800 mg BID
Normalized name: Cadisegliatin
DrugBank: Cadisegliatin (DB18886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Study: NCT05681728
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
Study: NCT05681728
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
Study: NCT05681728
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
Study: NCT05004675
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 284 mg
Study: NCT05269628
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex® dose will be 0.5 mL (50 mg) twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 1 mL (100 mg) twice daily for the remainder of the treatment interval (full dose). If the full dose (100 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (50 mg twice daily).~Participants who go back to the half-dose of Cannabidiol (50 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 100 mg Cannabidiol per day. Participants who are tolerating the full-dose of medication (Cannabidiol 100 mg twice daily) will not be allowed to combine these doses into one daily dose.
Study: NCT05269628
Drug: Tetrahydrocannabinol (THC)
Normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol dose will be 2.5 mg twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 5 mg twice daily for the remainder of the treatment interval (full dose). If the full dose (5 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (2.5 mg twice daily).~Participants who go back to the half-dose of Dronabinol (2.5 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 5 mg Dronabinol per day. Participants who are tolerating the full-dose of medication (Dronabinol 5 mg BID) will not be allowed to combine these doses into one daily dose.
Study: NCT00413751
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05968885
Drug: Combine Mirabegron and Solifenacin.
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination pharmacotherapy
Study: NCT06530706
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
Study: NCT06676319
Drug: Lunsekimig
Normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
Study: NCT06676319
Drug: Fluticasone/salmeterol
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Study: NCT06676319
Drug: Budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Study: NCT05817201
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
Study: NCT05817201
Drug: Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
Study: NCT05063370
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
Study: NCT05911997
Drug: MTC 01
Normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slurry to be administered via colonoscopy
Study: NCT05911997
Drug: Fecal Microbiota Transplantation (FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
Study: NCT06676631
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
Study: NCT05117008
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
Study: NCT04635059
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
Study: NCT06611163
Drug: Tildrakizumab 100 mg
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
Study: NCT06610890
Drug: Midazolam maleate
Normalized name: midazolam maleate
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 15mg tablet, one tablet at a time